Ag Biotechnology

MMJ PhytoTech Ltd (ASX:MMJ) Update on Shareholding in Harvest One (CVE:HVST)

🕔2/26/2018 8:19:12 AM

MMJ PhytoTech Limited (ASX:MMJ) notes the attached press release by Harvest One Cannabis Inc. (CVE:HVST) confirming that Harvest One intends to mandatorily convert certain of its convertible debentures into common stock on or about 28 March 2018. Post conversion, MMJ's current shareholding of 53,333,333 common shares in Harvest One will be 34.5% of the total outstanding shares.

Read Full Article

MMJ PhytoTech Ltd (ASX:MMJ) New CEO

🕔2/19/2018 8:18:00 AM

MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce the appointment of Jason Conroy as Chief Executive Officer of MMJ effective from 26 February 2018.

Read Full Article

MMJ PhytoTech Ltd (ASX:MMJ) Harvest One (CVE:HVST) Operational Update

🕔2/7/2018 9:27:14 AM

MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that TSX-V listed Harvest One Cannabis Inc. (CVE:HVST), of which MMJ holds 53,333,333 shares, has released an operational update on its wholly-owned horticultural subsidiary United Greeneries Ltd.

Read Full Article

MMJ PhytoTech Ltd (ASX:MMJ) Harvest One (CVE:HVST) Corporate Update

🕔2/1/2018 10:00:02 AM

MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that TSX-V listed Harvest One Cannabis Inc. (CVE:HVST), of which MMJ holds 53,333,333 shares, has announced the closure of its C$40,250,000 bought deal offering.

Read Full Article

Queensland Bauxite Ltd (ASX:QBL) Quarterly Activities Report

🕔2/1/2018 8:27:51 AM

Queensland Bauxite Limited (ASX:QBL) provides the Company's Quarterly Activities Report.

Read Full Article

MMJ PhytoTech Ltd (ASX:MMJ) Quarterly Activities Report

🕔1/31/2018 3:10:35 PM

MMJ PhytoTech Limited (ASX:MMJ) is pleased to provide its quarterly activities report for the period ended 31 December 2017.

Read Full Article

MMJ PhytoTech Ltd (ASX:MMJ) PhytoTech Therapeutics Phase 2 Clinical Trial Update

🕔1/31/2018 8:21:42 AM

MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that it has received results from the first 10 patients who participated in the Phase 2 clinical trial undertaken by MMJ's wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Ltd.

Read Full Article